Olivia Lang Schultes, Aneeta Hotwani , Patricia B Pavlinac , M Jahangir Hossain , Dilruba Nasrin , Richard Omore , Farhana Khanam , Flywell Kawonga , Paul F Garcia Bardales , Hannah E Atlas , Alex O Awuor , Henry Badji , Bakary Conteh , Jennifer Cornick , Erika Feutz , Sean R Galagan , Ensa Gitteh , Eric R Houpt , Junaid Iqbal , Sadia Islam , Furqan Kabir , Adama Mamby Keita , Jie Liu , Donnie Mategula , Chimwemwe Mhango , Md Parvej Mosharraf , Billy Ogwel , Caleb Okonji , Uduma Uma Onwuchekwa , Tackeshy Pinedo Vasquez , S M Azadul Alam Raz , Lucero Romaina-Cachique , Francesca Schiaffino , Milagritos D Tapia , Sharon M Tennant , Mohammad Tahir Yousafzai , Khuzwayo C Jere , Margaret N Kosek , Samba O Sow , James A Platts-Mills , Farah Naz Qamar , Elizabeth T Rogawski McQuade , Karen L Kotloff , John Benjamin Ochieng , Firdausi Qadri , EFGH Consortium
(medRxiv,, 2025-08)
Background
Shigella vaccine development is a critical priority due to high burden and long-term outcomes among children. Choosing a clinical efficacy endpoint for Shigella vaccine trials requires comparing existing diarrhea ...